Skip to content
Clinical Trials – home

Vseobecna Fakultni Nemocnice V Praze

Verified siteinfo

Czechia U Nemocnice 499/2, Nove Mesto, 128 00 Prague, Czechia

  • 158 trials recruiting
  • Plasma cell myeloma · Pulmonary arterial hypertension · Ovarian cancer
  • Adults and children

About Specializations

Vseobecna Fakultni Nemocnice V Praze in Prague, Czechia specialises in clinical trials of conditions such as Plasma cell myeloma, Pulmonary arterial hypertension, Ovarian cancer, Cardiac amyloidosis, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory and Pediatric Allergy Research

At Vseobecna Fakultni Nemocnice V Praze, clinical trials in respiratory tract diseases focus on asthma in children, with an emphasis on improving symptom control and lung function through new treatment options.

  • Evaluating whether newer inhaled therapies can improve breathing outcomes in pediatric asthma
  • Comparing treatment effectiveness to support better long-term disease management

This area of research aims to strengthen care for young patients living with chronic airway disease.

Inflammatory Bowel Disease Studies

The site also supports research in immune system diseases and digestive system disorders, especially Crohn's disease in children and adolescents, with trials designed to assess how well emerging therapies work and how safe they are.

  • Testing treatments for moderately to severely active pediatric Crohn's disease
  • Assessing treatment response in patients who have not benefited from standard therapies

These studies help advance care for young people facing persistent intestinal inflammation.

Rare Genetic and Growth Disorder Research

Research in congenital, hereditary, and neonatal diseases at this Prague hospital includes studies in osteochondrodysplasia, particularly achondroplasia, with a focus on safety and early treatment evaluation.

  • Studying therapies for children with rare skeletal growth disorders
  • Exploring whether new approaches may support better disease management and functional outcomes

This work reflects a strong interest in rare pediatric conditions and inherited disorders.

Broader Immune and Developmental Research

Beyond the main diseases studied, the clinical program covers immune system processes and related pediatric conditions, showing a broad interest in how inflammation and development affect child health.

  • Investigating therapies that may improve control of immune-mediated disease
  • Supporting research into pediatric conditions with complex developmental and inflammatory features

With a large investigator base, the department contributes to a diverse portfolio of clinical research in children.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
U Nemocnice 499/2, Nove Mesto128 00 PragueCzechia
Recruiting now
158 trials
Conditions studied
224
Partner status
Verified site

More sites in PragueCzechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

431 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Narcolepsy

Recruiting

Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Narcolepsy

Recruiting

Phase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Torticollis

Recruiting

Study on IPN10200 for Treating Cervical Dystonia in Adults

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
  • Sponsor:Ipsen Innovation
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.